GULP1 Up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GULP1 Up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GULP1 Up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GULP1 Up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GULP1 Up.

Results found

Linked to

 

Label

Description

 

Gene

ENSG00000146859 - transmembrane protein 140

Gene

ENSG00000163106 - hematopoietic prostaglandin D synthase

Gene

ENSG00000106927 - alpha-1-microglobulin/bikunin precursor

Gene

ENSG00000166128 - RAB8B, member RAS oncogene family

Gene

ENSG00000152926 - zinc finger protein 117

Gene

ENSG00000105875 - WD repeat domain 91

Gene

ENSG00000162267 - inter-alpha-trypsin inhibitor heavy chain 3

Gene

ENSG00000052723 - suppressor of IKBKE 1

Gene

ENSG00000113851 - cereblon

  • Gene

    ENSG00000146859 - transmembrane protein 140


  • Gene

    ENSG00000163106 - hematopoietic prostaglandin D synthase


  • Gene

    ENSG00000106927 - alpha-1-microglobulin/bikunin precursor


  • Gene

    ENSG00000166128 - RAB8B, member RAS oncogene family


  • Gene

    ENSG00000152926 - zinc finger protein 117


  • Gene

    ENSG00000105875 - WD repeat domain 91


  • Gene

    ENSG00000162267 - inter-alpha-trypsin inhibitor heavy chain 3


  • Gene

    ENSG00000052723 - suppressor of IKBKE 1


  • Gene

    ENSG00000113851 - cereblon

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.